Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma

European Journal of Surgical Oncology

DOI: 10.1016/j.ejso.2006.10.032 OpenAlex

Authors 0

Author list not loaded yet.

Cited by 6 stored of 136

Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors
2025 European Journal of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

3

citations
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
2023 Nature Reviews Clinical Oncology review Medicine Cutaneous Melanoma Detection and Management

50

citations
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
2023 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

135

citations
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
2022 Nature Medicine article Medicine Cutaneous Melanoma Detection and Management Open access

378

citations
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
2022 JAMA Surgery article Medicine Cutaneous Melanoma Detection and Management Open access

55

citations
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
2022 Annals of Surgical Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

44

citations

6 results

Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma

Authors 0

Cited by 6 stored of 136

References 0